Navigation Links
Mount Sinai Grants Exclusive License to Plexcera Therapeutics to Develop Treatments for Farber Disease and Cystic Fibrosis
Date:9/11/2013

New York, NY (PRWEB) September 11, 2013

Mount Sinai Innovation Partners (MSIP), part of the Icahn School of Medicine at Mount Sinai, has granted an exclusive license to Plexcera Therapeutics, LLC to commercially develop recombinant human acid ceramidase (rhAC) to treat diseases caused by genetic or disease-induced deficiencies in the enzyme rhAC.

Mount Sinai is promoting the scientific discoveries of its faculty by facilitating the establishment and supporting incubator companies to accelerate the discovery of treatments for devastating diseases, including those that often affect relatively small populations.

Plexcera was founded by Edward H. Schuchman, PhD, Genetic Disease Foundation, Francis Crick Professor of Genetics and Genomic Sciences at the Icahn School of Medicine, and Ivan Galanin, a pharma industry veteran and an advisor to MSIP, in collaboration with QOL Medical LLC, a specialty pharma company focused on rare pediatric diseases.

Two devastating childhood diseases are caused by recessive inherited mutations in the gene encoding rhAC: Farber disease, characterized by severe joint pain, inflammation and arthritis, and, a form of spinal muscular atrophy with epilepsy (SMA-PME), found in adolescents, and characterized by progressive muscle weakness. There is no therapy for either condition. In addition, in cystic fibrosis, excess ceramide accumulates in the lungs. Treatment with inhaled rhAC may address lung cell death, inflammation and susceptibility to infection seen in these patients.

“The name ‘Plexcera’ comes from the concept that rhAC is an enzyme with multiple uses. Farber disease is our first target,” said Dr. Schuchman. “We hope to launch a clinical trial of rhAC within the next 18 months. "

The licensed technology is based on more than 20 years of research conducted by Dr. Schuchman, who will serve as Plexcera’s Chief Scientific Officer, and Erich Gulbins, PhD, from the Center for Medical Biotech at the University of Duisburg-Essen, Germany, who will serve on Plexcera’s Scientific Advisory Board. Dr. Schuchman has extensive research and development experience with these disorders and enzyme replacement therapy specifically. Dr. Gulbins has identified a central role for excess ceramide accumulation in cystic fibrosis, as well as other pulmonary diseases.

“Mount Sinai has a strong track record of developing breakthrough products for rare diseases. Dr. Schuchman has worked with key scientific, clinical and industry thought leaders for many years and can call on their expertise and commitment,” said Mr. Galanin, CEO of Plexcera. “The collaboration with QOL Medical gives us access to key infrastructure components such as clinical, regulatory and manufacturing expertise.”

As part of the license, Mount Sinai received equity in the new company, as well as royalties. This is the second major license agreement negotiated this year by MSIP in the field of orphan diseases, both originating from research conducted by the Department of Genetic and Genomic Sciences.

About Mount Sinai Innovation Partners
Mount Sinai Innovation Partners (MSIP), part of the Icahn School of Medicine at Mount Sinai, facilitates the transfer of discovery from the laboratory to the marketplace, acting as the interface with commercial entities.

MSIP is responsible for the full spectrum of commercialization activities required to bring the Icahn School of Medicine’s inventions to life. These activities include evaluating, patenting, marketing, and licensing new technologies, while also negotiating agreements for sponsored research, material transfer, and confidentiality. For more information on MSIP, visit: http://www.mountsinai.org/innovation

About Plexcera Therapeutics, LLC
Plexcera Therapeutics was founded with the goal of bringing life-saving therapies to patients who have either a genetic deficiency in the acid ceramidase enzyme or a disease-driven imbalance between the enzyme and its substrate. The company is headquartered in Vero Beach, FL, with facilities in New York City. For more information on Plexcera Therapeutics, please visit: http://www.plexcera.com.

About QOL Medical LLC
QOL Medical LLC, based in Vero Beach, is a specialty biopharmaceutical company focused on pediatric products for genetic and rare orphan diseases. QOL invests in clinical stage and marketed products and currently markets 2 approved products: Sucraid (sacrosidase) Oral Solution for Congenital Sucrase-Isomaltase Deficiency and Ethamolin (Ethanolamine Oleate) Injection 5% for bleeding esophageal varices.    For more information on QOL, please visit: http://www.qolmed.com.

About The Mount Sinai Medical Center
The Mount Sinai Medical Center encompasses both The Mount Sinai Hospital and Icahn School of Medicine at Mount Sinai. Established in 1968, the Icahn School of Medicine is one of the leading medical schools in the United States, with more than 3,400 faculty in 32 departments and 14 research institutes. It ranks among the top 20 medical schools both in National Institutes of Health (NIH) funding and by U.S. News & World Report. The Mount Sinai Hospital, founded in 1852, is a 1,171-bed tertiary- and quaternary-care teaching facility and one of the nation’s oldest, largest and most-respected voluntary hospitals. The Mount Sinai Hospital is nationally ranked by U.S. News & World Report as one of the top 25 hospitals in 7 specialties based on reputation, safety, and other patient-care factors.

For more information, visit http://www.mountsinai.org/.

Find Mount Sinai on:
Facebook: http://www.facebook.com/mountsinainyc
Twitter @mountsinainyc

Media contact: Mount Sinai Press Office, 212-241-9200, newsmedia(at)mssm(dot)edu

Read the full story at http://www.prweb.com/releases/2013/9/prweb11108351.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related medicine news :

1. GranuFlo Lawsuits Mount, as Bernstein Liebhard LLP Notes New Consolidated Litigation for GranuFlo Recall Claims Filed in Massachusetts State Court
2. Mount Sinai Receives NIH Grant to Increase the Engagement of African Americans in Colorectal Cancer Screening
3. Janina A. Longtine, MD of the Icahn School of Medicine at Mount Sinai Elected President of the Association for Molecular Pathology
4. Mount Sinai receives NIH grant to increase colorectal cancer screenings in African Americans
5. GranuFlo Lawsuit News: Bernstein Liebhard LLP Comments on Fresenius FDA Warning Letter, as GranuFlo Recall Claims Mount
6. Mount Sinai Experts Share Tips for Ovarian Cancer Awareness Month in September
7. Researchers from Mount Sinai receive NIH grant to study promising treatment for Autism subtype
8. Music for Relaxation
9. “Sculptations” Helps People Create Enormous Amounts of Money to Live a Life of Comfort and Happiness – V kool
10. Mount Sinai and Exosome Partner to Accelerate Translation of Body Fluid Molecular Diagnostics to Overcome Limitations of Tissue Biopsy in Areas of Unmet Medical Needs
11. Amerinet and NML Collaborate with Intermountain Healthcare on Integrated Supply Chain Center
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/31/2016)... ... 2016 , ... TeaZa® Energy, LLC announces the launch of a ... Tobacco Day . The new flavor—Tropical TeaZa? Energy—will be available to customers exclusively ... The new flavor is best described as a juicy, taste bud takeover. A ...
(Date:5/31/2016)... Penn. (PRWEB) , ... May 31, 2016 , ... ... skills to apply information technology solutions to the healthcare industry, The University of ... graduate-level program offers an accelerated path to a career in rapidly growing field ...
(Date:5/30/2016)... ... May 30, 2016 , ... Zane Benefits, the ... of an original infographic, " Health Benefits Reimbursement Compliance Timeline ." , ... Benefits complies with various federal regulations and reforms. , Navigating the new health ...
(Date:5/29/2016)... (PRWEB) , ... May 29, 2016 , ... "With 30 ... let's the user control the style of their project," said Christina Austin - CEO ... 30 self-animating web-themed intros created exclusively for use in Final Cut Pro X. Pixel ...
(Date:5/28/2016)... ... ... city where’s it’s easy to spot the neon lights of chains serving fast food, one ... a taste for real food. , On May 13, the Best Western Plus ... restaurant focusing on dishes made by hand with wholesome, organic ingredients that are sourced locally ...
Breaking Medicine News(10 mins):
(Date:5/26/2016)... May 26, 2016 According to a ... Management Market - U.S. Industry Analysis, Size, Share, Growth, Trends, ... in the U.S. was valued at US$ 5.89 Bn in ... 3.4% from 2015 to 2023 to reach US$ 7.99 Bn ... current and emerging needle free drug delivery devices and the ...
(Date:5/26/2016)... , May 26, 2016 ... With Both Cost Savings and Overall Decreased ... (LSE: BTG), an international specialist healthcare company, has ... the 21st Annual Meeting of ISPOR (International Society ... of hepatocellular carcinoma (HCC) using yttrium-90 glass microspheres ...
(Date:5/26/2016)... Since its commercial introduction in ... life science tool for conducting genetic studies in a ... in its new report that the industry sits on ... by a range of new applications in the clinical ... http://photos.prnewswire.com/prnh/20140723/694805 ) , Since the Human ...
Breaking Medicine Technology: